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SHORT COMMUNICATION
Tumor vasculature is a key determinant for the efﬁciency of
nanoparticle-mediated siRNA delivery
LL i 1, R Wang1, D Wilcox1, X Zhao2, J Song2, X Lin1, WM Kohlbrenner1, SW Fesik1 and Y Shen1
Delivering small interfering RNA (siRNA) to tumors using clinically viable formulations remains the primary technical hurdle that
prevents the development of siRNA therapy for cancer treatment. Over the past several years, signiﬁcant effort has been devoted
to explore novel delivery strategies, whereas relatively little attention has been paid to understand the impact of physiological
constrains such as tumor vasculature on the efﬁciency of siRNA delivery. Using the previously described positive-readout tumor
models where successful siRNA delivery leads to an upregulation of b-galactosidase within tumor sections, we analyzed the
spatial distribution of localized target knockdown within tumor sections relative to tumor hypoxia and found that stable nucleic
acid lipid particle (SNALP), a lipid nanoparticle-based delivery system, predominantly delivers siRNA to areas adjacent to
functional tumor blood vessels. Increasing tumor vascularity by ectopic expression of VEGF resulted in more efﬁcient siRNA
delivery to tumors using SNALP. SNALP-mediated delivery of a siRNA-targeting Ran GTPase led to target knockdown and
signiﬁcant antitumor efﬁcacy in the highly vascularized HepG2-derived liver tumors, but not in the poorly vascularized
HCT-116-derived liver tumors. These results highlight the signiﬁcant impact of tumor vasculature on siRNA delivery and call for
a more focused effort on addressing tumor penetration after extravasation, an area of only limited attention currently.
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INTRODUCTION
Small interfering RNA (siRNA) represents a promising, novel ther-
apeutic modality for the treatment of complex diseases such as
cancer.1,2 However, delivering siRNA to tumors using clinically viable
formulations remains the major technical hurdle. Over the past several
years, signiﬁcant effort has been devoted to explore novel delivery
strategies,3–9 whereas relatively little attention has been paid to under-
stand the impact of physiological constrains such as tumor vasculature
on the efﬁciency of siRNA delivery. We have previously reported the
successful development of positive-readout models for evaluating
siRNA delivery to tumors.10 These models employ a siRNA designed
to target the tet repressor (TetR) as a surrogate for siRNA delivery.
Functional delivery of the TetR siRNA into tumors results in a robust
upregulation of reporter signal that can be detected by immuno-
histochemistry (IHC; b-galactosidase model created using the TetR-
ODC-LacZ cells) or bioluminescence imaging (luciferase model
created using the TetR-ODC-Luc cells).10 Using these positive-readout
tumor models, we screened various literature-described delivery
systems and identiﬁed stable nucleic acid lipid particle (SNALP) as
a promising siRNA delivery platform. Although SNALP mediates
more efﬁcient siRNA delivery than any other delivery systems that
we examined, it only delivers siRNA to 10–15% of tumor cells in our
in vivo models.10 In this study, we investigated the underlying causes
for this limited tumor cell coverage and identiﬁed tumor vasculature
as a key determinant for the efﬁciency of SNALP-mediated siRNA
delivery.
RESULTS AND DISCUSSION
SNALP delivers siRNA to normoxic regions within tumor
In our earlier studies, we tested the ability of SNALP to deliver the
TetR siRNA into tumors using the TetR-ODC-LacZ model. In this
model, successful delivery of the TetR siRNA causes an increase of
b-galactosidase expression that can be easily monitored via IHC
detection of b-galactosidase in tumor sections. We found from these
studies that, unlike doxycycline treatment, which induced b-galacto-
sidase expression in all tumor cells, SNALP-mediated delivery of the
TetR siRNA only induced b-galactosidase expression in a small
fraction (B10–15%) of cells in a tumor section,10 suggesting
that SNALP delivers siRNA to some but not all areas within the
TetR-ODC-LacZ tumor. We speculated that the differential responses
to SNALP-mediated siRNA delivery in various areas within tumor
may reﬂect the different accessibility of these regions to functional
tumor vasculature. Our initial attempt on testing this hypothesis by
correlating where functional siRNA delivery occurs (regions with
positive b-galactosidase staining) with local microvessel density failed
to establish a clear relationship between tumor vasculature and
SNALP-mediated siRNA delivery (data not shown). We suspect that
a direct examination of blood vessels within a particular region may
not accurately reﬂect the accessibility of this region to functional
circulation for both physiological and technical reasons. For example,
tumors often contain abnormal and non-functional blood vessels, and
vessels adjacent to a tumor area may not appear in the same tumor
section depending on the orientation of the vessel (an adjacent vessel
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www.nature.com/gtruns in parallel to the section could be missing from the section). To
circumvent these issues, we used tumor hypoxia as a marker to assess
the accessibility of a particular tumor area to functional circulation,
with the assumption that hypoxic regions are farther away from
functional tumor vessels relative to normoxic regions. We adminis-
tered SNALP that contains the TetR siRNA to mice bearing the TetR-
ODC-LacZ tumors. Before tumor harvesting, we dosed the mice with
the hypoxia probe, pimonidazole HCl. IHC analysis of adjacent serial
tumor sections was carried out with one section stained for
b-galactosidase expression and the adjacent section stained for the
hypoxia probe. Interestingly, b-galactosidase expression was almost
exclusively detected in areas free of hypoxia probe staining (Figure 1).
The apparent mutual exclusivity between the b-galactosidase staining
(an indicator of successful siRNA delivery) and the hypoxia probe
staining suggests that SNALP primarily delivers siRNA to the non-
hypoxic regions within tumor, which are likely areas that are adjacent
to functional tumor blood vessels.
Increasing tumor vascularity facilitates SNALP-mediated siRNA
delivery
If SNALP-mediated siRNA delivery indeed occurs adjacent to func-
tional tumor blood vessels, one would expect that better-vascularized
tumors will respond better to SNALP-mediated siRNA delivery. To
test this hypothesis, we took advantage of the previously described
positive-readout luciferase model (tumor models generated using the
TetR-ODC-Luc cells), which allows for rapid quantiﬁcation of siRNA
delivery to tumors in vivo, to compare the efﬁciency of SNALP-
mediated siRNA delivery to tumors with different degrees of vascu-
larization. We established TetR-ODC-Luc-derived cell lines that
express high levels of VEGF (TetR-ODC-Luc/VEGF cells). Under
in vitro tissue culture conditions, SNALP containing the non-targeted
control siRNA (NTC) did not induce luciferase expression in either
TetR-ODC-Luc cells or TetR-ODC-Luc/VEGF cells (Figure 2a, TetR-
ODC-Luc (NTC) and TetR-ODC-Luc/VEGF (NTC)). Meanwhile,
SNALP containing the TetR siRNA triggered a similar increase of
luciferase expression in both cell lines (Figure 2a, TetR-ODC-Luc
(siTetR) and TetR-ODC-Luc/VEGF (siTetR)). These results suggest
that VEGF expression does not change the response of cultured cells to
SNALP-mediated siRNA delivery. When inoculated in the liver,
the VEGF-expressing TetR-ODC-Luc/VEGF cells formed more-
vascularized tumors compared with tumors derived from the parental
TetR-ODC-Luc cells (Figure 2b). Feeding mice with doxycycline, a
small molecule inducer that is expected to trigger reporter expression
in all tumor cells regardless of tumor vascularization pattern, caused a
similar increase of luminescent signals in both the VEGF-expressing
and non-expressing tumors, suggesting that VEGF-expression does
not alter the intrinsic response of the reporter system in vivo
(Figure 2c). By contrast, intravenous administration of SNALP-
encapsulated TetR-siRNA led to a more dramatic increase of biolu-
minescent signal in the TetR-ODC-Luc/VEGF cell-derived tumors
compared with tumors derived from the parental TetR-ODC-Luc
cells (Figure 2d), suggesting that better siRNA delivery was achieved
in the more-vascularized, VEGF-expressing tumors. Taken together,
these results provided additional evidence that SNALP-mediated
Hypoxia Probe β-Galactosidase
Hypoxia Probe β-Galactosidase
Figure 1 SNALP delivers siRNA to normoxic areas within tumor sections. Mice bearing the TetR-ODC-LacZ-derived liver tumors were administrated with
SNALP liposomes containing the TetR siRNA on day 1 and day 4 (intravenous (i.v.), 2.5mg siRNA per kg). In all, 0.2ml pimonidazole HCl solution
(6mg per ml in saline) was administrated via i.v. injection 1h before sample harvesting on day 7. Adjacent sequential serial sections of the same tumor were
analyzed for b-galactosidase expression (right panel) and tumor hypoxia (left panel). Tumors from ﬁve mice were analyzed, and two representative ﬁelds were
shown here. Equivalent regions in adjacent sections are highlighted using dotted lines. (a) Field 1 at  5 magniﬁcation. (b) Field 2 at  10 magniﬁcation.
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Gene TherapysiRNA delivery appears dependent on the nature of the tumor
vasculature, with better delivery occurring in highly vascularized
tumors.
SNALP triggers better target knockdown in highly vascularized
tumors
Both of the positive-readout cell lines, TetR-ODC-LacZ and TetR-
ODC-Luc, are engineered cell lines originated from the MDA-MB435
parental cells. Although positive-readout models derived from these
cell lines allowed us to take a close look at the spatial relationship of
functional siRNA delivery and tumor vasculature, conclusions from
these artiﬁcial systems need to be veriﬁed in more physiologically
relevant models. Toward this end, we decided to examine the knock-
down of an endogenous target in standard xenograft tumor models
that have different degrees of vascularization. We generated liver
tumors using standard cancer cell lines HCT116, DLD-1, HepG2,
and HuH7. Hematoxylin and eosin staining of tumor sections revealed
that these xenograft tumors appeared to have very different
vasculature. The HCT116- and DLD-1-derived liver tumors have a
compact structure and very few blood vessels, whereas HepG2 and
HuH7-derived tumors contain a large number of vessels that are ﬁlled
with red blood cells (Figure 3a). As VEGF is a key factor impacting
tumor vascularity, we set out to determine whether the extensive
vascularization in HepG2 and HuH7 tumors were driven by
high levels of tumor VEGF. Surprisingly, lower levels of VEGF were
present in HepG2 and HuH7 tumors compared with HCT116 and
DLD-1 tumors, suggesting that the extensive vascularization in
HuH7 and HepG2 tumors may result from a VEGF-independent
mechanism (Figure 3b). Administrating SNALP containing
DY647-labeled siRNA to the mice bearing HepG2 or HCT116 liver
tumors resulted in clear DY647 ﬂuorescent signal across the HepG2
tumor section. In contrast, only very weak DY647 signal was observed
in HCT116 tumor section, suggesting that more SNALP liposome
reaches the highly vascularized HepG2 tumor compared with the
poorly vascularized HCT116 tumor (Figure 3c). Furthermore,
administrating SNALP containing a potent siRNA (sense strand:
5¢-GUGUGCCACCUCAUUAUUAdTdT-3¢) that targets a previously
described essential gene, Ran GTPase,11 led to a signiﬁcant reduction
of Ran protein in the highly vascularized, HepG2-derived liver tumors
but not in the poorly vascularized, HCT116-derived liver
tumors, indicating that better siRNA delivery was obtained in the
more-vascularized tumors (Figures 3d and e). As controls, SNALP
containing a NTC did not produce target knockdown in either of
these models.
Regular 
TetRODC-Luc tumor
VEGF-overexpressing 
TetRODC-Luc/VEGF tumor
Regular
TetRODC - Luc tumor
1
2
3
4
5
6
7
8
9
NTC siTetR NTC siTetR
S
i
g
n
a
l
 
R
a
t
i
o
 
(
D
a
y
4
/
D
a
y
0
)
0 0
5
10
15
20
25
30
35
40
45
Dox - Dox + Dox - Dox +
TetR-ODC-Luc TetR-ODC-Luc/VEGF
S
i
g
n
a
l
 
R
a
t
i
o
 
(
D
a
y
4
/
D
a
y
0
)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
-1.5 -1 -0.5 0 0.5 1 1.5 2
TetR-ODC-Luc (siTetR) TetR-ODC-Luc (NTC)
TetR-ODC-Luc/VEGF (siTetR) TetR-ODC-Luc/VEGF (NTC)
N
o
r
m
a
l
i
z
e
d
 
L
u
c
i
f
e
r
a
s
e
 
A
c
t
i
v
i
t
y
VEGF-overexpressing
TetRODC - Luc/VEGF tumor
Log(nM of siRNA)
Figure 2 Increasing tumor vascularization facilitates SNALP-mediated siRNA delivery. (a) The ability of SNALP liposome to deliver the TetR siRNA (siTetR)
or the control siRNA (NTC) into TetR-ODC-Luc or TetR-ODC-Luc/VEGF cells in vitro was determined. Different amounts of SNALP liposomes containing
siTetR or NTC were incubated with the TetR-ODC-Luc or TetR-ODC-Luc/VEGF cells for 72h, and luciferase activity in cells was determined afterwards.
The increase of luciferase activity indicates successful siRNA delivery. The x axis represents the dose of SNALP liposome in Log(nM of ﬁnal siRNA
concentration). SNALP-mediated delivery of TetR siRNA induced a similar dose–response curve in the TetR-ODC-Luc and the TetR-ODC-Luc/VEGF cells,
indicating that high level of VEGF expression does not change the intrinsic response of the positive-readout system to siRNA delivery. (b) Representative
tumor sections (hematoxylin and eosin staining) of the regular TetR-ODC-Luc tumors and the VEGF-expressing TetR-ODC-Luc/VEGF tumors. (c)T h e
TetR-ODC-Luc or TetR-ODC-Luc/VEGF cells were used to create liver tumors via intrahepatic inoculation in scid mice. Mice were imaged on day 0, fed
with regular water (Dox ) or doxycycline-containing water (Dox+) for 4 days, and reimaged on day 4. (d) Mice that bear TetR-ODC-Luc- or TetR-ODC-Luc/
VEGF-derived liver tumors were administrated with SNALP liposomes containing the control siRNA (NTC) or the TetR siRNA (siTetR) via intravenous injection
(2.5mg siRNAkg 1) on day 1 and day 2. Mice were imaged 1 day before the start of dosing (day 0) and 2 days after the last dose (day 4). For both (c, d)
N¼5 for each treatment group. Each bar in the graph represents the average signal ratio±s.e.m. for each group.
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Gene TherapyTherapeutic siRNA delivered using SNALP exhibits better efﬁcacy
against highly vascularized tumors
To further determine to what degree tumor vasculature will impact
therapeutic efﬁcacy, we compared the antitumor efﬁcacy of
SNALP-siRAN in the HepG2-derived liver tumor model and the
HCT116-derived liver tumor model. Intravenous administration of
SNALP-siRAN at 2mg siRNA per kg, twice per week for three weeks
caused signiﬁcant tumor growth inhibition in the HepG2 model but
not in the HCT116 model (Figure 4a). In contrast, under in vitro
culture conditions, SNALP-siRAN induced signiﬁcant cell death in
both HCT116 (half maximal effective concentration (EC 50)
B0.2nM) and HepG2 cells (EC 50B1n M) with more robust cell
killing observed in the HCT116 cells over HepG2 cells at similar
SNALP-RAN concentrations (Figure 4b). These results suggest that
HCT116 cells are more sensitive to SNALP-siRAN than HepG2 cells
when exposed to similar level of SNALP-siRAN. Therefore, the lack of
in vivo efﬁcacy in HCT116 tumors likely reﬂects less efﬁcient siRNA
delivery to the poorly vascularized HCT116 tumors rather than a
result of intrinsic resistance of the HCT116 tumor to SNALP-siRAN.
In summary, in addition to serving as a frontline screening tool to
identify promising delivery platforms for further optimization, the
positive-readout tumor model makes it possible to distinguish
between areas within tumors where effective delivery occurs versus
areas that are less accessible to the delivery. By studying the spatial
distribution of localized target knockdown within tumor sections
relative to tumor hypoxia, we found that SNALP appears to
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Figure 3 SNALP triggers better target knockdown in highly vascularized tumors. (a) Liver tumors were established via intrahepatic injection of HCT116 or
HepG2 cells in scid mice. Representative hematoxylin and eosin sections of the HCT116- and HepG2-derived liver tumors were shown. (b) VEGF levels in
tumor homogenates (N¼5 for each tumor type) were determined using the QuantiGlo human VEGF kit and normalized to the total protein amount in the
same sample. (c) SNALP liposome containing DY647-labeled TetR siRNA were administrated to tumor-bearing mice (intravenous (i.v.), 2.5mg siRNAkg 1).
Tumors were harvested 20h later and cryosections of the tumor were stained with an antibody that recognizes a human speciﬁc mitochondria marker.
Representative confocal image of resulted HepG2 or HCT116 sections were shown. Blue: human mitochondria staining that speciﬁcally labels xenograft
tumor tissue. Red: DY647 signal that indicates the presence of SNALP(siRNA) delivery. (d) Mice that bear HCT116- and HepG2-derived liver tumors were
administrated with SNALPs-containing NTC or siRAN at 2mg siRNAkg 1, i.v., q.d.  2. Tumors were collected 48h after last dosing and analyzed by
western blotting for the expression of Ran and Actin. N¼4 for each treatment group. (e) Densitometry quantiﬁcation of western results in (d). The y axis
represents the average amount of Ran (normalized to the amount of actin in each sample).
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Gene Therapypredominantly deliver siRNA to areas adjacent to functional tumor
blood vessels. This result is largely in line with the notion that large
particles can only travel a short distance after extravasation from
tumor blood vessels. Because of this limitation, tumor vasculature
becomes a key determinant for the efﬁciency of SNALP-mediated
siRNA delivery. The signiﬁcant impact of tumor vasculature on
nanoparticle-mediated siRNA delivery described here could have
important ramiﬁcations in choosing the optimal tumor types and
siRNA targets for a therapeutic siRNA program. Because many
nanoparticle-based delivery vehicles are expected to be restricted to
cells adjacent to tumor vasculature like SNALP, these delivery systems
may be better suited to deliver an antiangiogenic siRNA that targets
the tumor vasculature versus delivering a cytotoxic siRNA that targets
the tumor cells. Alternatively, therapeutic formulations containing a
cytotoxic siRNA may be more efﬁcacious in patients with highly
vascularized tumors where the delivery formulation can reach a
sufﬁcient number of tumor cells to produce signiﬁcant antitumor
efﬁcacy. It is noteworthy that the HCT116- and HepG2-derived liver
tumors exhibited dramatically different responses to SNALP-mediated
delivery of a therapeutic siRNA despite that both tumors were grown
in the liver. This result suggests that despite the prevailing enthusiasm
of targeting liver tumors in the therapeutic siRNA ﬁeld, some liver
tumors may not be viable candidates for nanoparticle-based siRNA
therapy. The differential response of HCT116- and HepG2-derived
liver tumors suggest that better therapeutic response to SNALP or
other nanoparticle-based therapeutic siRNA formulations will be
more likely obtained in typically highly vascularized primary hepato-
cellular carcinomas than in less-vascularized tumors such as liver
metastases of colorectal carcinomas. Although, in a general sense, the
impact of tumor vasculature on nanoparticle-mediated delivery is not
surprising, it is enlightening that the delivery efﬁciency of SNALP, the
perceived current state of art in siRNA delivery, is still severely limited
by tumor vascularity. Understanding this limitation not only has
important implications on patient selection and choice of therapeutic
targets as discussed above, it also calls for a more focused effort on
addressing tumor penetration after extravasation, which is an area of
limited attention currently.
MATERIALS AND METHODS
Cell culture and reagents
The HCT116, DLD-1, HepG2 and HuH7 cells were obtained from ATCC
(Manassas, VA, USA) and cultured in vendor-recommended media. The TetR-
ODC-Luc and TetR-ODC-LacZ cells were MDA-MB435-derived positive-read-
out cell lines that were described earlier.10 To generate the TetR-ODC-Luc/
VEGF cells, TetR-ODC-Luc cells were transfected with pcDNA6 plasmid that
encoding the VEGF gene, and stable clones were selected and tested for VEGF
expression. Cell proliferation was determined use the CellTiter Glo kit
(Promega, Madison, WI, USA). All siRNAs were purchased from Dharmacon
(Lafayette, CO, USA).
Tumor models
The animal studies were carried out in accordance with the internal Institu-
tional Animal Care and Use Committee guidelines at Abbott Laboratories.
Cancer cells were directly injected into the liver of scid female mice to generate
liver tumor models. All animals were obtained from Charles River Laboratory
(Wilmington, MA, USA). All cell lines used for creating xenograft tumors were
subjected to the IMPACT proﬁle I test (18 agents) at the University of Missouri
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Figure 4 Therapeutic siRNA delivered using SNALP exhibits better efﬁcacy against highly vascularized tumors. (a) HepG2 and HCT116 cells were used to
create liver tumors in scid mice via intrahepatic inoculation. At 72h after inoculation, mice were either untreated or administrated with empty SNALP
liposome, SNALP liposomes containing NTC or siRNA-targeting Ran (siRAN; intravenous, 2.5mg siRNAkg 1, twice per week) for 3 weeks. Tumor weight in
each mouse was determined 72h after the last dosing. %T/C (the ratio between the mean tumor weight of treated mice (T) and that of control mice (C)) was
calculated as the average tumor weight in treated mice versus the average tumor weight in untreated group. N¼15 for each treatment group, and
the average %T/C ±s.e.m. was plotted. (b) HCT116 and HepG2 cells were incubated with different amounts of SNALP containing a NTC or siRAN, and the
number of viable cells was determined 72h later using the CellTiter Glo kit.
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found negative for the 18 infectious agents tested.
Animal dosing and sample harvesting
For in vivo knockdown evaluation in positive-readout models, treatments were
started 3–4 weeks after tumor inoculation for liver tumors. For doxycycline
treatment in the TetR-ODC-Luc model, doxycycline (Sigma, St Louis, WA,
USA) was supplied in drinking water at a concentration of 1mgml 1 for 4 days
before imaging. For siRNA treatment in the positive-readout models, formu-
lated siRNAs were administrated via tail vein injection at the indicated dose and
schedule. For antitumor efﬁcacy evaluation, at the end of the efﬁcacy trial, mice
were humanly euthanized, liver tumor nodules were surgically excised and
weighted. For mice without visible tumors, the tumor weight was recorded as 0.
IHC analysis
IHC was carried out as previously described.12 Brieﬂy, tumors were excised, cut
into pieces of o3mm in thickness and immediately ﬁxed in buffered formalin
solution with neutral pH (Sigma, St Louis, MO, USA). The formalin-ﬁxed and
parafﬁn-embedded tumor sections were then used for staining. The mouse
anti-b-galactosidase mAb (Promega) was used to detect b-galactosidase in
tumor sections. IHC analysis of tumor hypoxia was carried out using the
Hypoxyprobe-1 kit (Natural Pharmacia International Inc., Burlington, MA,
USA) according to the manufacturer’s suggested protocol. Brieﬂy, 0.2ml
pimonidazole HCl solution (6mgml 1 in saline) was administrated via
intravenous injection 1h before tumor harvesting. The hypoxic areas within
tumor sections were detected using mouse antibody recognizing the protein
adduct formed by hypoxyprobe. For all IHC studies,3,3¢-diaminobenzidine was
used as the chromogen, and IHC images were acquired using the Nikon
TE2000 inverted microscope.
Bioluminescence imaging and analysis
In vivo bioluminescence imaging and analysis were conducted on the IVIS 200
system using the Living Image acquisition and analysis software (Caliper Life
Science, Hopkinton, MA, USA) as previously described.10 Brieﬂy, after intra-
peritoneal injection of luciferin (Promege, Madison, WI, USA) at 150mgkg 1,
mice were anesthetized with isoﬂuorane. At 4min after the injection of
luciferin, a series of time-lapse images were acquired at 2min intervals for a
total of 10min. Regions of interest were drawn around the tumors and signal
intensity was quantiﬁed as the sum of photon counts per second within the
Regions of interest after the subtraction of background luminescence. The peak
reading during the 10-min imaging period was used for calculating the signal
ratio before and after siRNA delivery.
Liposome formulation
The SNALP liposomes were prepared according to the literature-described
procedure.6 D-Lin-DMA and PEG-C-DMA were synthesized in-house and
formulated with distearoylphosphatidylcholine (DSPC), Cholesterol and siRNA
using a 25:1 lipid/siRNA ratio and a 48/40/10/2 molar ratio of Cholesterol/
D-Lin-DMA/DSPC/PEG-C-DMA. The resulted SNALP liposomes have similar
characteristics to what was described in the literature (80–100nm in size,
PDIo0.1, and a close to neutral zeta potential).
Quantitation of human VEGF within xenograft tumors
Tumors were homogenized in CelLytic-M (Sigma) with protease inhibitors.
After centrifugation, the concentration of human VEGF in supernatant were
measured using the QuantiGlo human VEGF kit (R&D systems, Minneapolis,
MN, USA). The total protein concentration of lysate was used to normalize the
human VEGF level in each tumor.
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